Androgen receptor and enzymes in lymph node metastasis and cancer reoccurrence in triple-negative breast cancer

International Journal of Biological Markers

Volumn 30, Issue 2, 2015, Pages e184-e189

  McNamara, Keely May ^a   Yoda, Tomomi ^a   Miki, Yasuhiro ^a   Nakamura, Yasuhiro ^a   Suzuki, Takashi ^a   Nemoto, Noriko ^a   Miyashita, Minoru ^a   Nishimura, Reiki ^b   Arima, Nobuyuki ^b   Tamaki, Kentaro ^a   Ishida, Takanori ^a   Ohuchi, Noriaki ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO CITY HOSPITAL   (Japan)

Author keywords

Androgen receptor; Breast cancer; Intracrinology; Metastasis; Triple negative breast cancer

Indexed keywords

17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 5; ANDROGEN PRODUCING ENZYME; ANDROGEN RECEPTOR; ENZYME; KI 67 ANTIGEN; OXIDOREDUCTASE; STEROID 5ALPHA REDUCTASE 1; UNCLASSIFIED DRUG;

ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CLINICAL ARTICLE; DISEASE FREE INTERVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; LYMPH NODE METASTASIS; PREVALENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION; TRIPLE NEGATIVE BREAST CANCER; BLOOD; FEMALE; LYMPH NODE; METABOLISM; PATHOLOGY;

FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; RECEPTORS, ANDROGEN; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84934757075     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000132     Document Type: Article

References (17)

1. Garay JP, Park BH. Androgen receptor as a targeted therapy for breast cancer. Am J Cancer Res. 2012;2(4):434-445.
2. Hickey TE, Robinson JL, Carroll JS, Tilley WD. Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol. 2012;26(8):1252-1267.
3. McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T, Sasano H. Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol. 2013;133:66-76.
4. Yeap BB, Krueger RG, Leedman PJ. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology. 1999;140(7):3282-3291.
5. McNamara KM, Yoda T, Nurani AM, et al. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes. Breast Cancer Res Treat. 2014;145(2):281-293.
6. McNamara KM, Yoda T, Miki Y, et al. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation. Cancer Sci. 2013;104(5):639-646.
7. Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol. 2011; 9:131.
8. Cimino-Mathews A, Hicks JL, Illei PB, et al. Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in endstage metastases found at autopsy. Hum Pathol. 2012;43(7): 1003-1011.
9. Sutton LM, Cao D, Sarode V, et al. Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma. Am J Clin Pathol. 2012;138(4):511-516.
10. McGhan LJ, McCullough AE, Protheroe CA, et al. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol. 2013.
11. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-1948.
12. Hung MH, Liu CY, Shiau CY, et al. Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients. PLoS ONE. 2014;9(2):e89389.
13. Koo JS, Jung W, Jeong J. Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site. Tumori. 2010;96(3):424-432.
14. Salhia B, Kiefer J, Ross JT, et al. Integrated genomic and epigenomic analysis of breast cancer brain metastasis. PLoS ONE. 2014;9(1):e85448.
15. Brogi E, Murphy CG, Johnson ML, et al. Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. Ann Oncol. 2011;22(12):2597-2603.
16. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple- negative breast cancer. Oncologist. 2013;18(2):123- 133.
17. Shibahara Y, Miki Y, Sakurada C, et al. Androgen and androgenmetabolizing enzymes in metastasized lymph nodes of breast cancer. Hum Pathol. 2013;44(10):2338-2345.